STADA and Grünenthal agreed on the purchase of a branded product portfolio also for the EU markets in Central Europe at a lower purchase price

STADA Arzneimittel AG  / Key word(s): Mergers & Acquisitions

27.01.2012 17:01

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, January 27, 2012 - Today, on January 27, 2012, STADA
Arzneimittel AG and Grünenthal GmbH have agreed on the purchase of a
branded product portfolio including the associated sales structures, also
for the EU markets in Central Europe (including Poland).

STADA had originally withdrawn from this acquisition (see ad hoc release of
May 12, 2011 on the start of contract negotiations as well as the ad hoc
update of July 22, 2011 on the signing of the contracts, each published via
DGAP), which had been pursued since May 2011, on January 1, 2012 within the
scope of contractual possibilities (see ad hoc release of January 1, 2012
on the withdrawal from purchase of the branded product portfolio in Central
Europe, published via DGAP).

Today, however, it was possible to successfully conclude subsequent
negotiations with the seller. The purchase price for the branded product
portfolio including sales structures and various pipeline products for
Central Europe now amounts to a total of approx. EUR 160 million and is
thus approx. EUR 48 million below the originally planned purchase price for
this product package of approx. EUR 208 million. Payment of the purchase
price will be made at the time of completion of the acquisition. Completion
is scheduled for January 31, 2012, now that all responsible anti-trust
authorities have approved the agreed transaction. In such a case the
branded product portfolio for Central Europe will be consolidated in the
STADA Group as of February 1, 2012.

On December 30, 2011, STADA had already successfully concluded the
purchase of the branded product portfolio including the associated sales
structures for numerous national markets in Eastern Europe (including
Russia, Ukraine, etc.) as well as the Middle East (see ad hoc update of
December 30, 2012 on the conclusion of the purchase in Eastern Europe as
well as the Middle East, published via DGAP).

Together with the transaction which was agreed today, the purchase of the
Grünenthal products in all originally planned markets is thus carried out.
The investments made by STADA in this regard are thus reduced, as a result
of the purchase price reduction agreed on today, from the original total of
approx. EUR 360 million to the current total of approx. EUR 312 million.


Additional information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:
communications@stada.de /
Or visit us in the Internet at www.stada.com.


27.01.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Germany
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
              Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------